US equities |
SPCX $166.80 ▲+4.93% NVDA $236.52 ▲+1.10% MU $1,064.25 ▼-0.99% TSLA $377.57 ▲+1.88% MSFT $526.48 ▲+1.73% SNDK $1,715.40 ▼-0.27% INTC $116.77 ▼-2.15% META $745.54 ▲+2.40%
FinancialContent

Articles published by QIAGEN N.V.

< Previous 1 2 3 4 Next >
News headline image
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN and BD Settle Patent Infringement Lawsuit
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
News headline image
QIAGEN Receives U.S. Department of Defense Contract to Further Expand Production Capacity for NeuMoDx
From QIAGEN N.V.
Via Business Wire
Tickers QGEN
< Previous 1 2 3 4 Next >